Trilogy Capital Inc. bought a new stake in Cardinal Health, Inc. (NYSE:CAH - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 2,120 shares of the company's stock, valued at approximately $356,000.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Wellington Management Group LLP raised its stake in shares of Cardinal Health by 1,666.7% during the 1st quarter. Wellington Management Group LLP now owns 2,384,192 shares of the company's stock worth $328,470,000 after buying an additional 2,249,241 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Cardinal Health by 40.0% during the 1st quarter. JPMorgan Chase & Co. now owns 4,175,992 shares of the company's stock worth $575,327,000 after buying an additional 1,193,983 shares during the last quarter. Zurich Insurance Group Ltd FI raised its stake in shares of Cardinal Health by 4,935.9% during the 1st quarter. Zurich Insurance Group Ltd FI now owns 946,750 shares of the company's stock worth $130,434,000 after buying an additional 927,950 shares during the last quarter. Nuveen LLC acquired a new position in shares of Cardinal Health during the 1st quarter worth $106,065,000. Finally, T. Rowe Price Investment Management Inc. acquired a new position in shares of Cardinal Health during the 1st quarter worth $104,951,000. Institutional investors and hedge funds own 87.17% of the company's stock.
Cardinal Health Price Performance
CAH opened at $157.79 on Thursday. The stock has a market capitalization of $37.49 billion, a price-to-earnings ratio of 24.46, a price-to-earnings-growth ratio of 1.33 and a beta of 0.71. The business has a 50-day moving average of $152.11 and a two-hundred day moving average of $149.90. Cardinal Health, Inc. has a 12 month low of $106.98 and a 12 month high of $168.44.
Cardinal Health (NYSE:CAH - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported $2.08 EPS for the quarter, beating the consensus estimate of $2.03 by $0.05. The company had revenue of $60.16 billion during the quarter, compared to analysts' expectations of $60.91 billion. Cardinal Health had a negative return on equity of 74.45% and a net margin of 0.70%.The firm's revenue was up .5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.84 EPS. Cardinal Health has set its FY 2026 guidance at 9.300-9.500 EPS. Equities research analysts anticipate that Cardinal Health, Inc. will post 7.95 earnings per share for the current year.
Cardinal Health Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Wednesday, October 1st will be issued a dividend of $0.5107 per share. The ex-dividend date is Wednesday, October 1st. This represents a $2.04 dividend on an annualized basis and a dividend yield of 1.3%. Cardinal Health's payout ratio is presently 31.63%.
Insider Buying and Selling at Cardinal Health
In other news, insider Michelle D. Greene sold 13,500 shares of the business's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $148.82, for a total transaction of $2,009,070.00. Following the completion of the sale, the insider owned 14,976 shares in the company, valued at approximately $2,228,728.32. The trade was a 47.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ola M. Snow sold 28,151 shares of the business's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $148.94, for a total value of $4,192,809.94. Following the sale, the insider owned 15,431 shares of the company's stock, valued at $2,298,293.14. The trade was a 64.59% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 271,676 shares of company stock worth $40,489,525. Company insiders own 0.12% of the company's stock.
Wall Street Analysts Forecast Growth
CAH has been the subject of several research reports. Bank of America lifted their price target on Cardinal Health from $165.00 to $170.00 and gave the stock a "buy" rating in a research note on Tuesday, June 10th. Wall Street Zen downgraded Cardinal Health from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 2nd. Citigroup reiterated a "neutral" rating and set a $170.00 price objective (up previously from $157.00) on shares of Cardinal Health in a research report on Friday, June 13th. Robert W. Baird lifted their price objective on Cardinal Health from $197.00 to $203.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 13th. Finally, Leerink Partners dropped their price objective on Cardinal Health from $188.00 to $186.00 and set an "outperform" rating for the company in a research report on Tuesday, August 12th. Eleven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, Cardinal Health has a consensus rating of "Moderate Buy" and a consensus price target of $165.93.
Read Our Latest Research Report on Cardinal Health
About Cardinal Health
(
Free Report)
Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cardinal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardinal Health wasn't on the list.
While Cardinal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report